Calidi Biotherapeutics, Inc. (CLDI) Misses Q3 EPS by 46c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St futures up as oil slips; telecoms pressured by SpaceX spectrum deal
- Oil falls as Trump comments on Iran talks ease supply concerns
- UBS flags level in gold prices where dip buyers will likely emerge
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- Investors need sustained Fed cuts to move cash off sidelines: BofA's Hartnett
Tweet
Share
E-mailGet Alerts CLDI Hot Sheet
Join SI Premium – FREE
Calidi Biotherapeutics, Inc. (NYSE: CLDI) reported Q3 EPS of ($0.65), $0.46 worse than the analyst estimate of ($0.19).
For earnings history and earnings-related data on Calidi Biotherapeutics, Inc. (CLDI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- Jefferies Starts Plains All American (PAA) at Buy
- Profound Medical and Telix sign co-education deal on prostate care
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
